Almac Forms Academia-Industry Collaboration to Develop Green Chemicals
Almac announces its high level involvement in a synthetic biology project to develop novel routes to chemicals. Other partners in the academic–industry collaboration include Bangor University (Wales) and Hockley International (manufacturer and exporter of environmental health and industrial chemical products).
A grant of £1 million has been awarded to the research team by the Biotechnology & Biological Sciences Research Council and Technology Strategy Board. The funding is specifically targeted at bringing a novel chemical produced via an enzymatic route from under-utilised natural oil to the market.
Almac is currently performing the research and development work at its Northern Ireland-based laboratories. The company is partnering with scientific experts from both the University’s College of Natural Sciences and Hockley to progress the project over a three year period.
Professor Tom Moody, Head of Biocatalysis & Isotope Chemistry at Almac, commented: “Almac has cultivated considerable enzyme technology experience and expertise over the past decade and collaboration in this research is especially important for the development of green processes in this industry. Our expert team of scientists are excited to work on this project as we recognise the opportunity for researchers across industry and academia to work more closely together, sharing skills and knowledge to deliver truly excellent research that can make an impact not just on this project but also the UK. Indeed, we are delighted to be at the forefront of such partnerships.”
“It will form a close collaboration between Almac, Hockley and the University’s School of Biological Sciences, Biocomposites Centre,” explains Dr Viacheslav Tverezovskiy who is leading this research at Bangor University.
Frank Howard, MD and owner of Hockley International adds “We look forward to starting this major 3-year project in synthetic biology along with Almac and Bangor University which promises to be most exciting and scientifically challenging for us all.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance